PhaseBio Pharmaceuticals Selling, General and Administrative Expense of Revenue

Selling, General and Administrative Expense of Revenue of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative Expense of Revenue for the quarter ending September 29, 2021 was 1108.96% (a 3231.21% increase compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative Expense of Revenue increased by Infinity%
  • Annual Selling, General and Administrative Expense of Revenue for 2020 was 3931.25% (a 105.27% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2019 was 1915.13% (a 169.21% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2018 was 711.38% (a Infinity% increase from previous year)
  • Twelve month Selling, General and Administrative Expense of Revenue ending September 29, 2021 was 112.95% (a 4.67% increase compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative Expense of Revenue increased by Infinity% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
112.95% 107.91% 0.0% 0.0%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative Expense of Revenue of PhaseBio Pharmaceuticals

Most recent Selling, General and Administrative Expense of Revenueof PHAS including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative Expense of Revenue of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 1108.96% 33.29% 0.0%
2020 0.0% 0.0% 0.0% 987.19% 3931.25%
2019 479.45% 1163.07% 341.96% 354.67% 1915.13%
2018 871.98% 256.93% 0.0% 0.0% 711.38%
2017 0.0% 0.0%
2016 0.0%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.